Abstract |
This was an exploratory study of renzapride in 168 male and female patients with non-D, non-C irritable bowel syndrome (IBS). Patients were randomized to placebo or renzapride (1, 2, or 4 mg/day) for 8 weeks. The primary efficacy variable was patient-reported satisfactory relief of IBS symptoms. Secondary variables included relief of abdominal pain/discomfort. The proportion of patients reporting satisfactory relief of their IBS symptoms for at least 50% of the time did not differ significantly from those on placebo. However, post hoc analysis in women showed differences in responder rate on renzapride versus placebo of 18.2% (95% CI -5% to 42%; P = 0.066) during weeks 1-4 and 6% (95% CI -21% to 33%; P = 0.339) during weeks 5-8. Renzapride was well tolerated and most adverse events were mild to moderate in intensity. Further studies are warranted to determine whether renzapride is beneficial in this patient population.
|
Authors | R C Spiller, N L Meyers, R I Hickling |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 53
Issue 12
Pg. 3191-200
(Dec 2008)
ISSN: 0163-2116 [Print] United States |
PMID | 18465239
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzamides
- Bridged Bicyclo Compounds, Heterocyclic
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5-HT4 Receptor Agonists
- Serotonin Antagonists
- renzapride
|
Topics |
- Adult
- Benzamides
(therapeutic use)
- Bridged Bicyclo Compounds, Heterocyclic
(therapeutic use)
- Defecation
(physiology)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Electrocardiography
- Female
- Humans
- Irritable Bowel Syndrome
(classification, drug therapy, physiopathology)
- Male
- Middle Aged
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5-HT4 Receptor Agonists
- Serotonin Antagonists
(therapeutic use)
- Treatment Outcome
|